Enzyme Inhibition Mechanisms

Many drugs act by inhibiting an enzyme - reducing the rate at which it converts substrate to product. The mechanism of that inhibition (competitive, non-competitive, uncompetitive, or irreversible) shapes the drug's potency, its dependence on substrate concentration, and the durability of its effect, and it is a central design consideration in medicinal chemistry.

Definition

Enzyme inhibition is the reduction of an enzyme's catalytic activity by a molecule (the inhibitor) that binds the enzyme, characterised by an inhibition constant (Ki) and by whether binding is reversible or irreversible and how it relates to the substrate-binding site.

Scope

This topic covers the principal modes of enzyme inhibition and the kinetic parameters that describe them: the inhibition constant (Ki), the contrast between reversible and irreversible (covalent) inhibition, the competitive/non-competitive/uncompetitive classification, and mechanism-based ('suicide') inhibition. It is a mechanistic reference entry and does not give dosing or therapeutic recommendations.

Core questions

• What distinguishes competitive, non-competitive, and uncompetitive inhibition?
• How is inhibitory potency quantified by the inhibition constant Ki?
• How does reversible inhibition differ from irreversible (covalent) inhibition?
• What is mechanism-based (suicide) inhibition?
• Why does inhibition mechanism affect the duration of a drug's effect?

Key concepts

• Inhibition constant (Ki)
• Competitive inhibition
• Non-competitive inhibition
• Uncompetitive inhibition
• Reversible versus irreversible (covalent) inhibition
• Mechanism-based (suicide) inhibition
• IC50 and the Cheng-Prusoff relationship

Key theories

Michaelis-Menten framework for inhibition

Reversible inhibitors are classified by how they alter the apparent Km and Vmax of an enzyme: competitive inhibitors raise apparent Km, non-competitive inhibitors lower apparent Vmax, and uncompetitive inhibitors lower both, providing the kinetic basis for distinguishing inhibition modes.

Mechanisms

An inhibitor lowers enzyme activity by binding the enzyme and interfering with catalysis. A competitive inhibitor binds the active site and competes with substrate, so its effect can be overcome by raising substrate concentration; a non-competitive inhibitor binds elsewhere and reduces maximal velocity regardless of substrate; an uncompetitive inhibitor binds only the enzyme-substrate complex. Reversible inhibitors associate and dissociate in equilibrium, summarised by the inhibition constant Ki, and the Cheng-Prusoff relationship converts an observed IC50 into Ki by accounting for substrate concentration. Irreversible inhibitors form a stable covalent bond with the enzyme, abolishing activity until new enzyme is synthesised; mechanism-based ('suicide') inhibitors are processed by the enzyme into a reactive species that then inactivates it. Singh and colleagues review how covalent (irreversible) inhibition, long avoided over toxicity concerns, has re-emerged as a deliberate design strategy for durable target engagement.

Clinical relevance

Enzymes are a major class of drug targets, and the inhibition mechanism explains why some inhibitors are surmountable by accumulating substrate while others produce prolonged effects outlasting the drug's presence. This material is mechanistic and educational; it is not prescribing or dosing guidance.

Evidence & guidelines

Kinetic conventions for inhibition (Ki, IC50, inhibition mode) follow standard enzymology and medicinal-chemistry references; the Cheng-Prusoff relationship is the accepted method for relating IC50 to Ki.

History

The quantitative description of enzyme kinetics by Michaelis and Menten in 1913 provided the framework within which inhibition modes were later defined. Cheng and Prusoff's 1973 relationship gave a practical way to compare inhibitors by relating IC50 to the inhibition constant, and the design of covalent and mechanism-based inhibitors matured through the late twentieth century into a mainstream medicinal-chemistry strategy.

Debates

Are irreversible (covalent) inhibitors safe enough to design deliberately?

Covalent inhibitors offer durable, potent target engagement but raise concerns about off-target reactivity and immune-mediated toxicity; whether targeted covalency can be made reliably safe is an active design debate.

Key figures

• Leonor Michaelis
• Maud Menten
• Yung-Chi Cheng
• William Prusoff
• Robert Copeland

Seminal works

• cheng-prusoff-1973
• singh-2011
• overington-2006

Frequently asked questions

What is the difference between competitive and non-competitive inhibition?

A competitive inhibitor binds the active site and competes with substrate, so adding more substrate overcomes it; a non-competitive inhibitor binds a different site and lowers the enzyme's maximal rate in a way that more substrate cannot reverse.

Why can an irreversible inhibitor act longer than the drug is present?

An irreversible inhibitor forms a covalent bond that permanently inactivates the enzyme, so activity returns only as the cell synthesises new enzyme - an effect that can persist after the drug has been cleared.